I agree Twinvest,
It is long term commitment in biotech which allows for massive returns.
Even management gets caught out by prematurely underestimating the time periods necessary for global players to sign the deal.
Everything is progressing as it should, needless to say share price lingers at low levels as it is so often the case before
long awaited deals are finalised.
Market does not have the patience and MD is easy to control in stocks traded on low volume for a prolonged period of time.
email reply from ceo, geoff cumming, page-21
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
